{{cart_num}}
My Cart> Small Molecule Compounds > Inhibitors & Antagonists & Agonists > Cell Cycle > RabusertibCAS：911222-45-2
Molecular Formula：C18H22BrN5O3
Molecular Weight：436.3
Storage：Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year
Purity：≥98%
Appearance：Off-white to yellow Solid
Qty：
Size：
| CAS | 911222-45-2 |
| Name | Rabusertib |
| Molecular Formula | C18H22BrN5O3 |
| Molecular Weight | 436.3 |
| Solubility | Soluble in DMSO |
| Purity | ≥98% |
| Appearance | Off-white to yellow Solid |
| Storage | Powder:-20℃，2 years;Insolvent(Mother Liquid):-20℃，6 months;-80℃，1 year |
| MDL | MFCD18633253 |
| SMILES | BrC(C=C1NC(NC2=NC=C(N=C2)C)=O)=C(C=C1OC[C@H]3OCCNC3)C |
| Target Point | Checkpoint Kinase (Chk) |
| Passage | Cell Cycle |
| Background | LY2603618 is a potent and selective Chk1 inhibitor. |
| Biological Activity | LY2603618 是一种有效的选择性的 Chk1 抑制剂，IC50 为 7 nM[1]。 |
| IC50 | Chk1:7nM [1] |
| Data Literature Source | [1]. King C，et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32(2):213-26. [2]. Wang G，et al. Panobinostat synergistically enhances the cytotoxic effects of cisplatin，doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS One. 2013 Sep 30;8(9):e76662. |
| Unit | Bottle |
| Specification | 5mg 10mg |
Remark：These protocols are for reference only. Solarbio does not independently validate these methods.
Note：
1. The products are all for scientific research use only. Do not use it for medical, clinical diagnosis or treatment, food and cosmetics, etc. Do not store them in ordinary residential areas.
2. For your safety and health, please wear laboratory clothes, disposable gloves and masks.
3. The experimental results may be affected by many factors, after-sale service is limited to the product itself and does not involve other compensation.
Sorry, there is no more information.
Sorry, there is no more information.
Sorry, there is no more information.
Manual Download
